EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Impact of Empagliflozin Versus Dapagliflozin on Left Ventricular Remodeling in Heart Failure Patients: A 1‐Year Comparative Study

Mahmoud Balata, Marc Ulrich Becher, Marwa Hassan, Mohamed Rady, Shady Rashed, Usama Alkomi, Marian Christoph, Karim Ibrahim, Akram Youssef

Clinical Cardiology · 2025

DOI: 10.1002/clc.70192 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Cardiology, 2025. Verfasst von Mahmoud Balata und 8 weiteren Autor:innen. Beteiligte Einrichtung: Heart center, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Ventricular Remodeling. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) reduce cardiovascular mortality and heart failure (HF)‐related hospitalizations in HF patients. However, the mechanisms underlying these benefits remain unclear, and it is uncertain whether empagliflozin and dapagliflozin have differential effects on cardiac structure and function.

Aim

This study aims to compare the effects of these two SGLT2is on left ventricular echocardiographic parameters in HF patients over 1 year.

Methods

This retrospective study included 558 consecutive HF patients newly prescribed either dapagliflozin or empagliflozin. Key echocardiographic parameters, such as peak E‐wave velocity, E/e' ratio, left atrial volume index (LAVI), LV end‐diastolic and end‐systolic volumes (LV‐EDVI, LV‐ESVI), LV mass index (LV‐MI), relative wall thickness (RWT), LV sphericity index (LV‐SI), and ejection fraction (LVEF), were measured at baseline and after 1 year.

Results

At 1‐year, significant reductions were observed only in the empagliflozin group for peak E‐wave velocity (mean difference = −12.76 cm/s, 95% CI: −16.26 to −9.27, p < 0.001), E/e' ratio (mean difference = −3.04, 95% CI: −4.17 to −1.91, p < 0.001), and LV sphericity index (LV‐SI; mean difference = −0.01, 95% CI: −0.02 to −0.0005, p = 0.040). Both SGLT2is significantly improved E‐wave deceleration time, LAVI, LV‐EDVI, LV‐ESVI, LV‐MI, and LVEF. Neither medication produced significant changes in RWT, and no significant differences were noted between groups regarding HF hospitalizations or all‐cause mortality.

Conclusion

Empagliflozin demonstrated more pronounced effects on LV remodeling markers, including peak E‐wave velocity, E/e' ratio, and LV‐SI, compared to dapagliflozin. These findings suggest potential efficacy differences between SGLT2is, highlighting the need for future randomized comparative studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesHeart FailureVentricular RemodelingSodium-Glucose Transporter 2 InhibitorsVentricular Function, LeftHeart VentriclesHumansMaleFemaleRetrospective StudiesAgedStroke VolumeTreatment OutcomeMiddle AgedTime FactorsEchocardiographyFollow-Up Studies

Stichwörter der Autor:innen

SGLT2 inhibitorsdapagliflozinempagliflozinleft ventricular remodeling

Substanzen

Benzhydryl CompoundsGlucosidesempagliflozindapagliflozinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Heart center, University Hospital Bonn, Bonn, Germany.
  • Department of Internal Medicine and Cardiology, University hospital Rostock, Rostock.
  • Department of Internal Medicine and Cardiology, Städtisches Klinikum Solingen, Solingen, Germany.
  • Department of immunology, Theodor Bilharz Research Institute, Giza, Egypt.
  • Department of Internal Medicine and Cardiology, City Chemnitz Teaching Hospital, Medical Campus of the Technical University of Dresden, Chemnitz, Germany.

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Balata, M., Becher, M. U., Hassan, M., Rady, M., Rashed, S., Alkomi, U., Christoph, M., Ibrahim, K., & Youssef, A. (2025). Impact of Empagliflozin Versus Dapagliflozin on Left Ventricular Remodeling in Heart Failure Patients: A 1‐Year Comparative Study. Clinical Cardiology. https://doi.org/10.1002/clc.70192

Vancouver

Balata M, Becher MU, Hassan M, Rady M, Rashed S, Alkomi U, et al. Impact of Empagliflozin Versus Dapagliflozin on Left Ventricular Remodeling in Heart Failure Patients: A 1‐Year Comparative Study. Clinical Cardiology. 2025. doi:10.1002/clc.70192

BibTeX
@article{Balata2025,
  author = {Balata, Mahmoud and Becher, Marc Ulrich and Hassan, Marwa and Rady, Mohamed and Rashed, Shady and Alkomi, Usama and Christoph, Marian and Ibrahim, Karim and Youssef, Akram},
  title = {Impact of Empagliflozin Versus Dapagliflozin on Left Ventricular Remodeling in Heart Failure Patients: A 1‐Year Comparative Study},
  journal = {Clinical Cardiology},
  year = {2025},
  doi = {10.1002/clc.70192}
}
Kostenlos starten →